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Previous studies have shown that the transmembrane (TM) domain of the subtype B Vpu enhances virion release from cells and some
studies have shown that this domain may form an oligomeric structure with properties of an ion channel. To date, no studies have been
performed to assess the role of this domain in virus pathogenesis in a macaque model of disease. Using a pathogenic molecular clone of
simian human immunodeficiency virus (SHIVKU-1bMC33), we have generated a novel virus in which the transmembrane domain of the Vpu
protein was scrambled but maintained hydrophobic in nature (SHIVTM), which presumably would disrupt any ion channel TM properties of
this protein. Vectors expressing the Vpu as a fusion protein with the enhanced green fluorescent protein (VpuTMEGFP) indicate that it was
transported to the same intracellular compartment as the unmodified Vpu protein but did not down-regulate cell surface expression of CD4.
To assess the pathogenicity of SHIVTM, three pig-tailed macaques were inoculated with the SHIVTM and monitored for 6–8 months for
CD4+ T cell levels, viral loads and the stability of the sequence of the vpu gene. Our results indicated that unlike the parental SHIVKU-1bMC33,
inoculation of macaques with SHIVTM did not cause a severe CD4
+ T cell loss over the course of their infections. Sequence analysis of the
vpu gene analyzed from sequential PBMC samples derived from macaques revealed that the scrambled TM was stable during the course of
infection. At necropsy, examination of tissues revealed low viral loads and none of the pathology commonly observed in lymphoid and non-
lymphoid tissues following inoculation with the pathogenic parental SHIVKU-1bMC33 virus. Thus, these results show for the first time that the
TM domain of Vpu contributes to the pathogenicity of SHIVKU-1bMC33 in pig-tailed macaques.
D 2005 Elsevier Inc. All rights reserved.Keywords: Vpu; Transmembrane domain; Pathogenesis; SHIV; HIV-1Introduction
The Vpu protein is the smallest membrane protein
encoded by human immunodeficiency virus type 1 (HIV-
1), which consists of a short amino terminal domain, an
uncleaved signal sequence/transmembrane (TM) domain,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.04.038
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E-mail address: estephen@kumc.edu (E.B. Stephens).and a cytoplasmic domain consisting of two a-helices and
two highly conserved casein kinase sites (Hout et al., 2004;
McCormick-Davis et al., 2000a; Schubert et al., 1994).
Previous studies have shown that the Vpu protein has at
least two functions within HIV-1 infected cells. The first of
these functions involves the interaction of Vpu with the
CD4 molecule and subsequent shunting of CD4 to the
proteasome for degradation (Fujita et al., 1997; Schubert et
al., 1998). Both a-helices as well as the highly conserved005) 56 – 69
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cytoplasmic domain have been implicated in the CD4
down-regulation function (Paul and Jabbar, 1997; Schubert
et al., 1996b; Tiganos et al., 1998). The second function
associated with the Vpu protein is the ability to enhance
virion release from infected cells (Klimkait et al., 1990).
While the exact mechanism of the enhanced virion release is
unknown, some studies have associated this property with
the TM of Vpu (Schubert et al., 1996a). The TM of Vpu was
shown to form ion channels selective for some monovalent
or divalent cations but not to monovalent anions expressed
in frog oocytes (Ewart et al., 1996: Schubert et al., 1996a).
This ion channel activity was localized to the TM domain
and is independent from the cytoplasmic domain in
enhancing viral release from cells (Schubert et al., 1996b).
More recently, drugs have been identified that will interfere
with the Vpu-mediated virion release from cells (Ewart et
al., 2002, 2004).
To date, no studies have examined the function of the
Vpu transmembrane domain in a relevant animal model of
CD4+ T cell loss. The simian-human immunodeficiency
virus (SHIV) is a chimeric virus that contains the tat, rev,
vpu, and env genes in a genetic background of SIVmac239.
We and others have developed pathogenic SHIVs that are
capable of causing profound CD4+ T cell loss and AIDS in
both pig-tailed and rhesus macaques (Joag et al., 1996;
Luciw et al., 1999; Reimann et al., 1996; Stephens et al.,
2002). Our laboratory has been using a pathogenic simian-
human immunodeficiency virus (SHIV)/macaque model to
examine the role of Vpu in disease (Hout et al., 2004, Singh
et al., 2003). Using the pathogenic molecular clone
SHIVKU1bMC33, we previously showed that an intact Vpu
contributed to the CD4+ T cell loss that occurs during
infection with the pathogenic SHIV (Stephens et al., 2002)
and that disease in macaques only occurred if compensating
amino acid substitutions occurred in the Env and Nef
proteins (McCormick-Davis et al., 2000b; Singh et al.,
2001). In order to study the role the TM plays in vivo to
enhance pathogenesis, we constructed a mutant SHIV virus
(SHIVTM) in which the TM domain of the Vpu protein was
scrambled but kept hydrophobic as previously described
(Schubert et al., 1996b). In this study, we have analyzed the
in vitro replication of this virus and its ability to cause
CD4+ T cell loss and disease in macaques. Our results
indicate that SHIVTM was not as pathogenic to pig-tailed
macaques as the parental SHIVKU1bMC33, indicating that the
TM domain contributes in part to the rapid CD4+ T cell loss
and disease onset caused by SHIVKU1bMC33.Fig. 1. Sequence of the parental and scramResults
The intracellular transport properties of the VpuTM are the
same as the parental subtype B Vpu protein
The sequences of the unmodified and modified VpuTM
proteins are shown in Fig. 1. Before examining the role
of Vpu transmembrane domain in pathogenesis, we
analyzed the intracellular transport of the modified
VpuTM. To accomplish this, we fused the gene for
VpuTM to the gene of enhanced green fluorescent protein
(EGFP) using the same strategy we used to express the
unmodified subtype B Vpu (Pacyniak et al., in press;
Singh et al., 2003). To examine the intracellular trans-
port, we co-transfected 293 cells with vectors expressing
VpuEGFP and VpuTMEGFP and plasmids expressing an
intracellular marker for the Golgi complex (ECFP-Golgi),
the rough endoplasmic reticulum (DsRed2-ER), or
membranes including the cell plasma membrane (ECFP-
Mem). Co-transfection of 293 cells with the vectors
expressing the unmodified subtype B Vpu protein
(VpuEGFP) and either DsRed2-ER resulted in this
protein being partially co-localized with these intra-
cellular markers (Figs. 2A–D). Co-transfection with
vectors expressing the unmodified subtype B protein
(VpuEGFP) and ECFP-Golgi resulted in almost complete
co-localization (Figs. 2E–H). Co-expression of the
VpuEGFP with ECFP-Mem revealed that VpuEGFP
was not expressed on the cell surface, which is similar
to what we previously reported (data not shown). Co-
transfection of 293 cells with the vectors expressing
VpuTMEGFP and DsRed2-ER resulted in the partial co-
localization of the two proteins (Figs. 2I–L) while
co-transfection of 293 cells with vectors expressing
VpuTMEGFP and ECFP-Golgi resulted in almost com-
plete co-localization (Figs. 2M–P). Similar to unmodified
protein, co-transfection of 293 cells with a vector
expressing the VpuTMEGFP and ECFP-Mem markers
revealed partial co-localization and the VpuTMEGFP did
not appear to be on the cell surface (data not shown).
These results indicate that scrambling the amino acids of
the transmembrane domain still resulted in a protein that
was transported to the same intracellular compartment as
the unmodified Vpu protein and correlated well with
previous studies (Schubert et al., 1996b) as well as our
recent study in which we identified a region within the
cytoplasmic domain as having a Golgi retention signal
(Pacyniak et al., in press).bled Vpu proteins used in this study.
Fig. 2. The VpuTMEGFP protein is transported to the same intracellular compartment as the unmodified VpuEGFP. 293 cells were co-transfected with vectors
expressing the EGFP or VpuEGFP and DsRed2-ER or ECFP-Golgi. At 48 h, cells expressing EGFP and ECFP were examined and images collected using laser
scanning confocal microscopy as described in Materials and methods. (Panels A–D) 293 cells co-transfected with vectors expressing VpuEGFP and DsRed2-
ER. (Panel A) Expression of VpuEGFP. (Panel B) Expression of DsRed2-ER. (Panel C) Merge of panels A and B. (Panel D) Fluorescence micrograph of EGFP
and DsRed2 fusion proteins from panels A and B. (Panels E–H) 293 cells co-transfected with VpuTMEGFP and ECFP-Golgi. (Panel E) Expression of
VpuEGFP. (Panel F) Expression of ECFP-Golgi. (Panel G) Merge of panels E and F. (Panel H) Fluorescence micrograph of EGFP and ECFP fusion proteins
from panels E and F. (Panels I–L) 293 cells co-transfected with VpuTMEGFP and DsRed2-ER. (Panel I) Expression of VpuEGFP. (Panel J) Expression of
DsRed2-ER. (Panel K) Merge of panels I and J. (Panel L) Fluorescence micrograph of EGFP and DsRed2 fusion proteins from panels I and J. (Panels M–P)
293 cells co-transfected with VpuTMEGFP and ECFP-Golgi. (Panel M) Expression of VpuTMEGFP. (Panel N) Expression of ECFP-Golgi. (Panel O) Merge of
panels M and N. (Panel P) Fluorescence micrograph of EGFP and ECFP fusion proteins from panels M and N.
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CD4
To determine if the VpuTMEGFP was capable of
preventing cell surface expression of CD4, HeLa CD4+
cells were transfected with vectors expressing VpuEGFP,
VpuTMEGFP, and EGFP. At 48 h post-transfection, live cells
were stained for cell surface CD4, fixed and examined by
confocal microscopy. As shown in Figs. 3A–D, cells
expressing EGFP did not prevent CD4 expression while
transfection of HeLa CD4+ cells with a vector-expressing
VpuEGFP prevented cell surface expression (Figs. 3E–H),
which is similar to what we previously reported (Pacyniak et
al., in press; Singh et al., 2003). Transfection of HeLa CD4+
cells with the vector-expressing VpuTMEGFP resulted in
100% of the cells expressing CD4 on the cell surface (Figs.
3I–L). In addition to immunofluorescence studies, weexamined the ability of VpuTMEGFP to promote degrada-
tion of CD4. 293 cells were transfected with vectors
expressing human CD4 and either VpuEGFP, VpuTMEGFP,
or EGFP. At 48 h post-transfection, cells were radiolabeled
for 1 h followed by a chase period of 5 h. The results shown
in Fig. 3M show that the VpuEGFP caused degradation of
CD4 while the expression of EGFP or VpuTMEGFP did not
result in degradation of CD4. Taken together, these results
indicate that scrambling the TM domain of Vpu affected the
ability of Vpu to induce the degradation of CD4.
The Vpu protein from SHIVTM is expressed and has a
similar Mr on SDS-PAGE
We analyzed the expression of the Vpu protein in C8166
cultures inoculated with parental SHIVKU-1bMC33 or
SHIVTM. Cultures were inoculated with equivalent amounts
Fig. 3. CD4 down-modulation by EGFP, VpuEGFP, and VpuTMEGFP proteins. HeLa CD4
+ cells, which express CD4, were transfected with vectors expressing
EGFP, VpuEGFP, or VpuTMEGFP. At 48 h post-transfection, cells were stained for surface CD4 using a-CD4 antibody and a rhodamine conjugated secondary
antibody followed by fixation with 1% formalin. Cells were examined by laser scanning confocal microscopy. (Panels A, E, and I) Cells examined using a
fluorescein filter to visualize EGFP expression and layered onto a phase contrast image of the cell. (Panels B, F, and J) Cells were examined using a rhodamine
filter to identify cells expressing the CD4. (Panels C, G, and K) Merge of EGFP and CD4 images (for expression of Vpu fusion protein and CD4 expression).
(Panels D, H, and L) Fluorescent micrograph in which the EGFP and CD4 staining are overlayed. (Panels A–D) Cells transfected with a vector-expressing
EGFP. (Panels E–H) Cells transfected with a vector-expressing VpuEGFP. (Panels I–L) Cells transfected with a vector-expressing VpuTMEGFP. (Panel M)
The VpuTMEGFP fusion protein does not induce degradation of human CD4. 293 cells were transfected with vectors expressing human CD4 and either EGFP,
VpuEGFP, or VpuTMEGFP. At 48 h post-transfection, cells were starved for methionine and cysteine and radiolabeled with
35S-methionine/cysteine for 5 h.
Cell lysates were prepared in 1 RIPA buffer and the CD4 immunoprecipitated using a rabbit anti-human CD4 antibody and protein A Sepharose (PAS). The
immunoprecipitates were washed, boiled in sample reducing buffer and analyzed by SDS-PAGE (10% gel). (Lane 1) CD4 proteins immunoprecipitated from
cells co-transfected with vectors expressing human CD4 and VpuEGFP. (Lane 2) CD4 proteins immunoprecipitated from cells co-transfected with vectors
expressing human CD4 and VpuTMEGFP. (Lane 3) CD4 proteins immunoprecipitated from cells co-transfected with vectors expressing human CD4 and EGFP.
(Lane 4) CD4 proteins immunoprecipitated from non-transfected cells.
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labeled and Vpu proteins immunoprecipitated from cell
lysates. As shown in Fig. 4, a protein with an Mr of 16,000
was immunoprecipitated from SHIVKU-1bMC33-inoculated
cultures. A Vpu protein was also immunoprecipitated from
SHIVTM-inoculated C8166 cultures with similar but not
identical mobility by SDS-PAGE, reflecting the difference in
the sizes of the two proteins.
The SHIVTM virus is less cytopathic and replicates with
decreased kinetics compared to the parental SHIVKU-1bMC33
We compared the kinetics of replication of the
SHIVTM with the parental SHIVKU-1bMC33 in C8166cells. An equivalent number of TCID50 were used to
inoculate C8166 cells and the culture supernatants
analyzed for p27 levels at various times post-inoculation.
The results shown in Fig. 5 indicate that the SHIVTM
replicated with delayed kinetics compared to the parental
SHIVKU-1bMC33 virus. In addition, the cultures of C8166
cells inoculated with SHIVTM exhibited markedly less
and delayed syncytial cytopathology compared to cultures
inoculated with SHIVKU-1bMC33. Pulse-chase analyses
were also performed on infected cultures as we have
done in past studies and showed that p27 was released
from SHIVTM cultures with delayed kinetics when
compared to parental SHIVKU-1bMC33-infected cultures
(data not shown). Taken together, these results indicate
Fig. 4. Immunoprecipitation of Vpu proteins from SHIVKU-1bMC33 and
SHIVTM-inoculated cultures. C8166 cultures were inoculated with
SHIVKU-1bMC33 or SHIVTM at an MOI of approximately 0.01. Cultures
were incubated for 6 days and then radiolabeled with 35S-methionine/
cysteine for 5 h. Vpu proteins were immunoprecipitated from cell lysates
using an a-Vpu serum as described in Materials and methods. A similar
number of immunoprecipitated cpm from the SHIVTM-inoculated and
SHIVKU-1bMC33-inoculated cultures were analyzed under reducing con-
ditions by SDS-PAGE (12.5% gel) and visualized by standard autoradio-
graphic techniques. (Lane 1) Vpu proteins immunoprecipitated from
uninoculated cultures. (Lane 2) Vpu proteins immunoprecipitated from
SHIVTM-inoculated cultures. (Lane 3) Vpu proteins immunoprecipitated
from SHIVKU-1bMC33-inoculated cultures. The location of the molecular
weight markers is shown on the right.
Fig. 5. Growth curves of SHIVKU-1bMC33 and SHIVTM in C8166 cells.
Cultures of C8166 cells were inoculate with either SHIVKU-1bMC33 (.) or
SHIVTM (r) as described in the text. Aliquots of the culture medium was
assayed for the presence of p27 antigen. The growth curves were performed
in triplicate and the mean of the three experiments plotted.
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compared to the parental SHIVKU-1bMC33.
Electron microscopy reveals that SHIVTM has an altered
pattern of maturation in C8166 cells
As the p27 assays revealed that SHIVTM replicated with
reduced kinetics compared to the SHIVKU-1bMC33, we
examined infected lymphocytes (C8166 cells) by electron
microscopy to determine if differences existed in the
maturation of SHIVTM. As shown in Fig. 6A, C8166 cells
inoculated with the SHIVKU-1bMC33 matured at the cell
surface of infected cells and is similar to our previous
observations (Hout et al., 2004). In contrast, examination of
cultures of C8166 cells inoculated with the SHIVTM by
electron microscopy revealed fewer particles maturing at the
cell plasma membrane (Fig. 6B) although more cells
observed with virus within intracellular vesicles and
maturing into intracellular vesicles (Fig. 6C). Taken
together, these results indicate that the SHIVTM maturation
pattern was significantly different from the parental
SHIVKU-1bMC33.
The SHIVTM infects pig-tailed macaques but fails to cause
the rapid CD4+ T cell loss observed with the parental
SHIVKU-1bMC33
To assess the role of the fused vpu and env genes in CD4+
T cell loss in macaques, three pig-tailed macaques (CX59,
CW1K, and CX58) were inoculated with SHIVTM. CD4
+ T
cell counts and viral loads were then monitored over the
course of the infections (Fig. 7A). After inoculation withSHIVTM, the circulating CD4
+ T cell numbers in all three
macaques remained in the normal range from 2539 to 4233
cells/Al at week 0 and 1166 to 4033 cells/Al by week 4 post-
inoculation, which is a critical time for CD4+ Tcell loss in this
pathogenic SHIV model. From 4 weeks to 24 weeks, CD4+ T
cell numbers remained in the normal range and ranged from
1199 to 2454 cells/Al at 24 weeks post-inoculation. All three
macaques were euthanized in apparent good health at 24 or 32
weeks post-inoculation. The circulating CD4+ T cell levels
were significantly different to that seen in macaques
inoculated with parental SHIVKU-1bMC33, in which a severe
drop in the levels of circulating CD4+ T cells within 4 weeks
post-inoculation (Fig. 7B).
The plasma viral loads in animals inoculated with SHIVTM
were lower compared to the parental SHIVKU-1bMC33
We compared the plasma viral loads in the three
macaques inoculated with SHIVTM with the viral loads in
macaques inoculated with the parental SHIVKU-1bMC33.
As shown in Fig. 7C, all three macaques inoculated with
SHIVTM had viral loads that were significantly lower
than those from macaques inoculated with the parental
SHIVKU-1bMC33 (Fig. 7D).
The sequence of the vpu gene was stable during the course
of the macaque infection
In order to assess the stability of the vpu gene during the
course of infection, DNA was extracted from PBMC
samples at 1, 2, 3, 4, 6, 9, 12, 20 weeks, and at necropsy.
The vpu sequence was amplified, directly sequenced, and
compared to the input vpu sequence of the SHIVTM. No
Fig. 6. Examination of the SHIVTM and SHIVKU-1bMC33 maturation by electron microscopy. C8166 cells were inoculated with equivalent amounts of either
SHIVTM or SHIVKU-1bMC33 and at 5 days post-inoculation, cells were processed for electron microscopy. (Panel A) Maturation of SHIVKU-1bMC33 showing
typical maturation at the cell surface. (Panels B and C) Maturation of SHIVTM showing virus particles at the cell surface and budding into intracellular vesicles.
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during the course of the infection, indicating that the vpu
gene was stable (data not shown). We also analyzed the vpu
sequences analyzed from the mesenteric lymph node, spleen
and thymus at necropsy. Sequence analysis revealed that
like the PBMC sequences, the vpu sequences from the
mesenteric lymph node, spleen, and thymus remained stable
(data not shown).Fig. 7. Circulating CD4+ T cell levels and plasma viral loads following inoculatio
circulating CD4+ T cells in macaques CX58 (.) and CX59 (0), and CW1K (r
CD4+ T cells in four macaques (2000, .; 2001, n; CM4G, o; and CM4K, r)
levels in macaques inoculated with SHIVTM: CX58 (.), CX59 (0), and CW1K (
n; and CM4K, r) inoculated with SHIVKU-1bMC33. Samples were subjected to
Standard curves were generated using five dilutions of viral RNA of known coMacaques inoculated with SHIVTM exhibited less pathology
compared to parental SHIVKU-1bMC33
The distribution of virus in the various visceral tissues
was determined by PCR for viral 2-LTR sequences, which
is indicative of ongoing replication of the virus. As shown
in Table 1, viral 2-LTR sequences were detected in 4 of 13
tissues from CX58, 6 of 13 tissues from CX59, and 4 of 13n of macaques with SHIVTM and SHIVKU-1bMC33. (Panel A) The levels o
) following inoculation with SHIVTM. (Panel B) The levels of circulating
following inoculation with SHIVKU-1bMC33. (Panel C) Plasma viral RNA
r). (Panel D) Plasma viral RNA levels in three macaques (2000, .; 2001
real time RT-PCR and Taqman probe homologous to the SIV gag gene
ncentration.f
,
.
Table 1
Distribution of viral 2LTR sequences in tissues from macaques inoculated
with SHIVTM
a
Tissue Macaque
CX58 CX59 CW1K
Visceral organs
Heart () () ()
Kidney () () ()
Liver (+) () (+)
Lung () () ()
Pancreas () () ()
Salivary gland () () ()
Axillary lymph node () () ()
Inguinal lymph node () (+) ()
Mesenteric lymph node (+) (+) (+)
Small Intestine () (+) ()
Spleen (+) (+) (+)
Tonsil (+) (+) (+)
Thymus () (+) ()
CNS
Frontal cortex (+) () ()
Motor cortex (+) (+) ()
Parietal cortex () (+) ()
Occipital cortex () (+) ()
Temporal cortex (+) () ()
Cerebellum () () ()
Medulla () (+) ()
Pons () () (+)
Midbrain () () ()
Thalamus () () ()
Corpus callosum () () ()
Basal ganglia () () ()
Cervical spinal cord () () ()
Thoracic spinal cord () () ()
Lumbar spinal cord () () ()
a Tissue DNA samples were analyzed for 2-LTR sequences using nested
DNA PCR as described in the text.
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were positive for the presence of 2-LTR sequences were
lymphoid organs. We also analyzed the DNA samples iso-
lated from 15 regions of the CNS for gag and 2-LTR
sequen ces. Macaques CX58, CX59, and CW1K were
positive for 2-LTR sequences in 3 of 15, 4 of 15, and 1 of
15 regions of the CNS, respectively (Table 1). Histological
examination of lymphoid tissues (inguinal, axillary and
mesenteric lymph nodes, small intestine, thymus, tonsil,
spleen,) derived from the SHIVTM-inoculated macaques
revealed no significant lesions within these tissues (Fig. 8).
Similarly, no lesions were observed within the brain, heart,
kidney, lung, liver, pancreas, and salivary gland (data not
shown).
We also compared the number of cells having viral
sequences virus from the mesenteric lymph node, spleen
and thymus DNA samples isolated at necropsy. As shown
in Fig. 9, the numbers of cells containing viral sequences
was generally around 102 cells per 106 cells analyzed.
The number of cells producing infectious, cytopathic
virus ranged from <10 to 102 cells per 106 cells analyzed
(data not shown), which is lower than what we havereported for parental SHIVKU-1bMC33 (Stephens et al.,
2002).Discussion
Previous studies have shown that the Vpu protein forms
an oligomeric structure and modeling studies have sug-
gested that the Vpu ion channel appears to be an oligomer
composed of 5 transmembrane spanning a-helices deter-
mined by pore radius profiles and conductance predictions
(Cordes et al., 2001; Grice et al., 1997; Maldarelli et al.,
1993). A role for the TM domain of Vpu in virus
pathogenesis and its potential ion channel activity was
suggested from a study in which the TM was scrambled but
kept hydrophobic (Schubert et al., 1996b). This Vpu protein
was found to form an oligomeric structure, was transported
to the same intracellular compartments as the unmodified
Vpu, down-regulated CD4, but lacked the ion channel
activity associated with Vpu (Schubert et al., 1996b).
Further, these investigators showed that an HIV-1 virus
expressing this Vpu replicated with decreased kinetics and
was similar to Vpu-deficient viruses (Schubert et al.,
1996b). Using the above scrambled Vpu sequence as the
basis for the present study, we constructed a VpuTMEGFP
reporter construct using the same methods used to construct
the VpuEGFP (Pacyniak et al., in press; Singh et al., 2003)
and showed similar to the VpuEGFP, that the VpuTMEGFP
was localized to the RER and Golgi complex and was not
observed to be transported to the cell surface. However, in
contrast with a previous study, our VpuTMEGFP construct
did not prevent cell surface expression of CD4. While our
results are in contrast with those reported by Schubert et al.
(1996b) and we cannot provide an explanation for this
discrepancy, our results are consistent with other inves-
tigators in the field who showed that the transmembrane
domain contains amino acids/structural determinants that
affect CD4 down-regulation (Tiganos et al., 1998). We do
not believe that the inability of the VpuTMEGFP to down-
regulate CD4 was due to the Vpu fusion to the EGFP as we
have also constructed a chimeric Vpu protein in which the
TM domain was replaced with the TM domain of the M2
protein of influenza A virus. This construct, VpuM2EGFP,
was capable of CD4 down-regulation (unpublished obser-
vations). Furthermore, while VpuEGFP and VpuM2EGFP
were capable of forming oligomeric structures, we did not
observe the VpuTMEGFP to form an oligomeric structure,
suggesting that the formation of an oligomeric structure
may be necessary for CD4 down-regulation (unpublished
observations).
Currently, the only model available for assessing the role
of different domains of the Vpu protein in CD4+ T cell loss
and pathogenesis uses infection of macaques with a
pathogenic SHIV. Previously, we showed that inoculation
of macaques with the parental pathogenic SHIVKU-1bMC33
resulted in high virus loads, severe CD4+ T cell depletion
Fig. 8. Pathology associated with SHIVTM infection. Hematoxylin and eosin stains of sections from the mesenteric lymph node (Panels A and B), thymus
(Panels C and D) and spleen (Panels E and F) from macaque CX59 (Panels A, C, and E) and an SHIVKU-1bMC33 -inoculated macaque (Panels B, D, and F).
Fig. 9. The number of cells with viral sequences was determined by PCR-
ICA as described in the Material and methods section for cells isolated from
the mesenteric lymph node (MES), spleen (SPL), and thymus (THY) at
necropsy. An (*) indicates that cytopathic virus was not detected.
D.R. Hout et al. / Virology 339 (2005) 56–69 63and lesions consistent with severe lymphoid depletion
(Hout et al., 2004; Singh et al., 2003; Stephens et al.,
2002). Furthermore, we showed that the Vpu enhances the
pathogenicity of SHIVKU-1bMC33 in pig-tailed macaques
(Singh et al., 2001; Stephens et al., 2002). Recently, we
showed that removal of the highly conserved casein kinase
II sites in Vpu from SHIVKU-1bMC33, which previous
studies showed were essential to the interaction of Vpu
with CD4 (Paul and Jabbar, 1997), contributed to the
severe CD4+ T cell loss (Singh et al., 2003). Of the four
macaques inoculated with this SHIVS52,56G virus, one
developed a severe loss of CD4+ T cells. The one macaque
from this study that developed a rapid decline in CD4+ T
cells and progression to disease had a reversion of the two
casein kinase sites back to the parental SHIVKU1-bMC33
sequence. Using the scrambled TM amino acid sequence
from the study described above, we constructed the
SHIVTM to assess the role of this domain in the
pathogenicity caused by SHIVKU-1bMC33. We hypothesized
that the SHIVTM would have similar phenotypic character-
istics as previously described (Schubert et al., 1996b).
D.R. Hout et al. / Virology 339 (2005) 56–6964These include a decrease in virus release in vitro
determined by immunoprecipitation of viral proteins,
decreased growth replication kinetics determined by p27
growth curves, and differences in virion morphogenesis by
electron microscopy. The results of the pulse-chase
analysis, p27 growth curves, and electron microscopy
indicated that this virus replicated with reduced kinetics
when compared to the parental SHIVKU-1bMC33. Electron
microscopy revealed viral particles maturing at the cell
surface as well as within intracellular vesicles. As our
studies indicated that the VpuTMEGFP did not prevent CD4
down-regulation, we addressed the following question,
‘‘Does the TM domain contribute to the pathogenesis of
SHIVKU-1bMC33?’’ Three pig-tailed macaques were intra-
venously inoculated with SHIVTM and the plasma viral
loads, number of infected PBMC, number of PBMC
producing infectious virus, and genetic stability of the
vpu gene were analyzed for over 6 months. All three
animals maintained high levels of CD4+ T cells throughout
the infection until necropsy. Further viral loads determined
by PCR/ICA and RT-PCR showed a significant decrease in
the number of infected PBMCs and the ability to recover
virus release throughout the infection. Sequence analysis of
the vpu gene amplified from PBMC at different times after
inoculation (1, 2, 3, 4, 6, 9, 12, and 20 weeks as well as at
necropsy) revealed that all site-directed changes introduced
into the SHIVTMVpu TM were maintained throughout the
infection. In addition, we also analyzed the vpu sequences
from the three lymphoid tissues (mesenteric lymph node,
spleen and thymus), which showed that the TM domain
sequence was stable in all lymphoid tissues. This is not
surprising as 19 nucleotide changes were introduced in the
vpu gene resulting in 17 amino substitutions. We hypothe-
size that the lower levels of virus replication in the
macaques probably allowed the macaques to develop
effective immune responses against the virus to bring
replication under control. While we did not examine the
host cellular immune responses against the virus, we did
examine plasma at necropsy for neutralizing antibodies. All
three inoculated macaques developed neutralizing anti-
bodies against the SHIVTM (data not shown). Histopathol-
ogy of the tissues revealed the absence of lesions
characteristic of SHIVKU1bMC33 but was similar to the
histopathology of non-pathogenic SHIVs (Stephens et al.,
2002). Thus, the results presented here, together with our
previous results, indicate that both the TM domain and the
cytoplasmic domain have structural determinants that
contribute to the pathogenicity of SHIVKU-1bMC33.
Although we did not examine the ion channel activity
with our SHIVTM as a previous study had shown that this
protein had no ion channel activity, we have shown for
the first time that by scrambling the amino acids of the
TM domain leads to a significant decrease in viral loads
and a subsequent decrease in viral pathogenesis. While
the mechanism(s) involved in the Vpu-mediated enhanced
virus release is currently unknown, it could involve Vpuinteraction with a cellular protein or complex of proteins,
which facilitates virion release. Evidence in support of
this hypothesis has come in a recent study showing Vpu-
mediated enhanced viral release from certain human cell
lines but not simian cell lines (Varthakavi et al., 2003).
Alternatively, the ion channel that has been associated
with the Vpu TM domain (Ewart et al., 1996; Park et al.,
2003; Schubert et al., 1996a) could modify the local
environment of the cell to facilitate release. However,
definitive evidence linking the ion channel activity with
enhanced virus release or altered virus maturation are still
lacking. Studies are underway to determine if replaceQ
ment of the Vpu TM domain with the TM domain of the
M2 protein of the influenza A virus (albeit, with its
different ion selectivity), which is the most extensively
studied viroporin, would abrogate the effects of a
scrambled TM as in SHIVTM and restore the pathoge-
nicity of the virus.Materials and methods
Cells, plasmids, and viruses
The lymphocyte C8166 cell line was used for trans-
fections as well as indicator cells to measure infectivity and
cytopathicity of the viruses used in this study. C8166 cells
were maintained in RPMI-1640, supplemented with 10 mM
HEPES buffer pH 7.3, 2 mM glutamine, 5 Ag per ml
gentamicin, and 10% fetal bovine serum. The 293 cell line
was maintained in Dulbecco’ s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum and 5
Ag per ml of gentamicin. The HeLa CD4+ cell line was
obtained from the NIH AIDS Research and Reference
Reagents Branch and was maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum and 1
mg/ml of Geneticin (Gibco). The derivation of SHIVKU-
1bMC33 has been previously described (McCormick-Davis et
al., 2000b; Stephens et al., 2002).
Construction of SHIVTM
Construction of the SHIVTM virus containing the
scrambled transmembrane (TM) domain was accomplished
in several steps. Plasmid pUC19)SNvpu12, containing the
SphI to KpnI fragment of SHIVKU-1bMC33 in pUC-19 (and
coding for the tat, rev, vpu and 5V end of env) was used for
the site-directed mutagenesis studies. The plasmid used was
pUC19)SNvpu12 and the Quick-Change Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions. A
total of 19 site directed mutagenesis reactions were
performed resulting in 17 amino acids changed in the
predicted transmembrane domain (Fig. 1). Clones were
isolated, plasmids isolated and the entire insert sequenced to
determine if the mutations were introduced as expected and
to ensure that no additional changes were introduced during
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nated as pVpuTM that contained the desired mutations. This
plasmid was digested to completion with SphI/KpnI, the
450 base pair fragment isolated, and subcloned into
the p3VSHIVKU-1bMC33 plasmid as previously described
(McCormick-Davis et al., 2000a). The resulting plasmid,
p3VSHIVTM was used to construct an infectious virus known
as SHIVTM using procedures previously described (Liu et
al., 1999; McCormick-Davis et al., 2000a; Stephens et al.,
1998). Stocks of the virus were prepared and titered in
C8166 cells. The virus stock was examined by PCR
amplification of the vpu gene sequence and sequence
analysis to ensure the purity of the stock virus.
Construction of a vector-expressing VpuTMEGFP
In order to examine the intracellular transport and
localization of the Vpu with a scrambled TM domain, we
constructed a vector that expressed the VpuTM fused to the
gene expressing enhanced green fluorescent protein (EGFP).
The procedure for the construction of the VpuTMEGFP was
similar to that reported for construction of the VpuEGFP
(Pacyniak et al., in press; Singh et al., 2003). The vpu gene
from SHIVTM-infected C8166 cells was amplified by PCR,
with oligonucleotides containing flanking NcoI sides on
either side 5V and 3V ends of vpu. The 5V oligonucleotide that
was used for amplification was 5V-CCATGGCTACAGAT-
CATCAACATCCC-3V (sense), which introduced a NcoI site
(bolded) within the start codon. The 3V-oligonucleotide that
was used for amplification was is 5V-ACCCTACTTCTAC-
TAGACATGGGTACC-3V (antisense), which introduced a
NcoI site (bolded) just 3V to the vpu sequence. The PCR
product was isolated, cut with the restriction enzyme NcoI
and was cloned into the pGEMT-Easy vector (Promega)
according to the manufacturer’s instructions. This plasmid,
known as pvpuTM NcoI, was digested to completion using
the restriction endonuclease KpnI and NcoI, the vpu gene
fragment was gel purified and subcloned into KpnI/NcoI-
digested pEGFP vector (Clontech Laboratories) that has an
NcoI site at the 5V end of the egfp gene. The resulting
plasmid, known as pvpuTMEGFP, was sequenced to ensure
that: (a) the vpu gene was inserted in the proper orientation
and (b) the junction between the vpu and egfp genes was in-
frame. For expression studies, pvpuTMEGFP was digested
with restriction enzymes KpnI and StuI and sub-cloned into
the KpnI and EcoRV sites of eukaryotic expression vector
pcDNA 3.1(+). This plasmid construct, designated as
pcvpuTMEGFP, was sequenced in its entirety to check for
possible sequence changes that may have occurred during the
cloning process and used for expression studies in 293 cells.
Transfections and laser scanning confocal fluorescence
microscopy analysis
Plasmid vectors expressing VpuEGFP, VpuTMEGFP and
EGFP proteins were transfected in human 293 cells toassess their subcellular localization using a cationic
polymer (polyethylenimine) transfection reagent (ExGen
500, MBI Fermentas) following the manufacturer’s proto-
col. Briefly, 1–3  105 cells were seeded onto cover slips
in each well of a 6 well tissue culture plate 24 h prior to
transfection. Transfection was carried out on cultures that
were 50–60% confluent using 4.75 Ag plasmid DNA and
15.5 Al of ExGen 500 corresponding to 5 equivalents. Each
plasmid DNA sample was diluted in 300 Al of 150 mM
sodium chloride solution separately. Samples were vor-
texed gently and immediately centrifuged at low revolution
for a few seconds. Polyethylenimine was then added to the
plasmid DNA solution, mixed with a vortex and allowed to
stand at room temperature for 10 min. The 293 cells were
washed with serum-free media twice and 3.0 ml of serum-
free DMEM was added. The polyethylenimine/DNA
mixture was added to the cells and the plate swirled by
slow hand rotation for a couple of seconds. Culture plates
were centrifuged at 280g for 5 min and incubated at
37 8C for 30 min. The medium from transfected cultures
was replaced with fresh complete growth media and cells
were incubated at 37 8C in 5% CO2 atmosphere.
Transfected cells were observed by confocal micro-
scopy, which is known to have the advantage that
fluorescence can be detected from cells in different optical
sections. Transfected cells were grown in 35 mm Petri
dishes, and were prepared for confocal microscopy as
follows. Cells were rinsed briefly in phosphate buffered
saline (PBS, pH 7.2) at room temperature. The cells were
fixed in freshly prepared, ice cold, 1% paraformaldehyde
in 0.13M sodium phosphate pH 7.2 for 2 min. The fixative
was removed and the cells briefly rinsed in phosphate
buffered saline. The saline was removed, and one drop of
mounting media was placed on each dish. The mounting
media is composed of 75% glycerol, 25% 0.13 M sodium
phosphate buffer pH 8.0 plus 0.02% n-propyl gallate. A
square number one glass cover slip was placed over each
dish. The cells were imaged with a Zeiss LSM 510
confocal microscope in the upright configuration. The
objective used was a 63  1.4 n.a. Plan Apochromat.
Images were captured at 12 bit resolution with a pixel
array of 1024  1024 and a zoom of 2.0. The signal was
averaged 4 times per line. The EGFP was excited with
light at 488 nm (laser intensity 75% for all images), and
the emitted light was collected after passing through a 505-
nm long pass filter. The amplifier offset and gain were
identical for all images. The SC detector gain was
decreased from 692 nm to 618 nm for cells expressing
Vpu EGFP1 since the intensity of the signal resulted in
saturation. A Z stack of 20 optical slices was obtained so
that the entire cell was imaged from bottom to top. The
pinhole was set to 96 Am which at this wavelength
represents one airy unit. The optical section had a width of
0.7 Am. Simultaneous to the acquisition of the confocal
signal from the EGFP, a non-confocal transmitted light
image was obtained to provide a reference point for the
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the greyscale transmitted light image.
To confirm the presence of the Vpu fusion protein at
different subcellular compartments, a series of co-trans-
fection studies were performed using vectors expressing
either an ER marker fused to the fluorescent protein
DsRed2 (DsRed2-ER), a Golgi complex marker fused to a
cyano-variant of EGFP (pECFP-Golgi), or a membrane
marker fused to a cyano-variant of EGFP (pECFP-Mem).
293 cells were co-transfected with vectors expressing the
various Vpu fusion proteins and either DsRed2-ER, ECFP-
Golgi, or ECFP-Mem. At 48 h post-transfection, cells were
processed for confocal microscopy as described above, and
cells identified expressing both proteins. Fluorescent
digital images were obtained using a Zeiss LSM510
confocal microscope equipped with an Argon/2 laser (25
mW) for the excitation (488 nm, 50% laser power) and
detection (band pass 505–530 nm filter; BP505–530) of
EGFP, for the excitation (458 nm, 100% laser power) and
detection (band pass 475–525 nm filter; BP475–525) of
ECFP, and for excitation (558 nm, 100% laser power) and
detection (band pass 583 nm filter; LP560) of DsRed2.
Images were acquired in Multitrack channel mode
(sequential excitation/emission) with LSM510 (v 3.2)
software and a Plan-Apochromat 100 /1.4 Oil DIC
objective with frame size of 1024  1024 pixels. Detec-
tor gain was set initially to cover the full range of all
the samples and background corrected by setting the
amplifier gain, and all images were then collected under
the same photomultiplier detector conditions and pinhole
diameter.
Assays for detection of cell surface CD4 and degradation of
CD4
To determine if the VpuTMEGFP construct was capable
of promoting degradation of CD4 in transfected cells, we
employed HeLa CD4+ cells. Cultures of HeLa CD4+ in
which approximately 80–85% of the cells stained positive
for surface CD4 were re-cloned to obtain a population of
cells in which >99% of the cells stained positive for cell
surface CD4. Briefly, HeLa CD4+ cells were grown on
cover slips and transfected with pcvpuEGFP as described
earlier. At 48 h post-transfection, cells were washed twice
with wash buffer (PBS pH 7.2, containing 2% fetal calf
serum and 0.01% NaN3) and reacted with mouse anti-CD4
(clone SFCI12T4D11CD4, Beckman-Coulter, 1:500 dilu-
tion) for 45 min. After the incubation, cover slips were
washed three times and incubated with rhodamine-con-
jugated secondary antibody (goat anti-mouse, Chemicon,
1:50 dilution) for 35 min followed by washing five times
in buffer without serum. Cells were then fixed in 1%
formalin for 10 min, washed twice, equilibrated with anti-
fade buffer and mounted on microscope glass slides using
Anti-fade (Molecular Probes, Oregon). Cells were imme-
diately observed under a fluorescent microscope (NikonTE300) with fluorescein filter (for visualization of EGFP)
and rhodamine filters (for visualization of CD4 staining).
All the staining procedures were performed on ice and in
the dark. HeLa CD4+ cells transfected with EGFP alone
served as control for down-regulation of CD4 and cultures
of HeLa CD4+ cells treated with wash buffer instead of
primary antibody served as negative control for CD4
staining. A minimum of 400 EGFP-expressing cells were
counted.
In addition to detection of CD4 on the cell surface of
transfected HeLa CD4+ cells, co-transfection experiments
were performed using vectors expressing either VpuEGFP,
VpuTMEGFP, or EGFP and a vector expressing the human
CD4 protein (pCMV4Neo; Goldsmith et al., 1995). Cells
were transfected with Vpu fusion proteins and
pCMV4Neo vectors at a 3:1 ratio, respectively. This was
to insure that all cells transfected with the CD4-expressing
vector were also transfected with the vector expressing the
Vpu fusion proteins. At 48 h post-transfection, cells were
starved for methionine and then radiolabeled with 500 ACi
35S-methionine/cysteine for 1 h. The radiolabel was
removed and chased with 100  cold methionine/cysteine
for 4 h. Cells were lysed in RIPA buffer, lysates prepared
and the CD4 immunoprecipitated using a rabbit anti-CD4
(sc-7219; Santa Cruz Biotechnology) and protein A
Sepharose (PAS). Immunoprecipitates were collected,
washed three times with 1  RIPA and analyzed by
SDS-PAGE (10% gel). The negative controls for this study
was co-transfection with a vector-expressing EGFP and
the positive control was co-transfection with a vector-
expressing VpuEGFP (expressing the unmodified subtype
B Vpu).
p27 assays
Growth curves based on extracellular release of viral
p27 protein were performed on SHIVKU-1bMC33 and
SHIVTM virus stocks. Virus stocks were tittered by
performing a series of ten fold dilutions in medium
without serum and then inoculating a Ghost CD4+ cell
line, which expresses the green fluorescent protein (GFP)
under the control of the HIV-1 LTR. At 48 h post-
inoculation, the number of fluorescent cells (indicative of
infection by the virus and subsequent expression of the
GFP) were scored and titers determined. Cultures of 106
C8166 cells were inoculated with equivalent amounts of
infectious cell-free virus (1  103) for 4 h. At the end of 4
h, the cells were centrifuged at 400g for 10 min, the
supernatant removed and the cell pellet washed with 10 ml
of medium. This was repeated two additional times. The
cells were resuspended in RPMI-1640 supplemented with
10% FBS and antibiotics; this was considered as the 0 time
point of the assay. Cultures were incubated at 37 8C and
aliquots of the culture were removed at 0, 1, 3, 5, 7, and
10 days with fresh media added to cultures at days 3, 5,
and 7. The culture medium was removed, cells pelleted by
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using antigen capture assays (Coulter) according to the
manufacturer’s instructions.
Electron microscopy
Infected cells were examined by electron microscopy to
determine the site of maturation. Cultures of C8166 cells
were inoculated with SHIVKU-1bMC33 or SHIVTM at a
multiplicity of infection of 0.01. Cells were incubated for a
total of 5 days at which time cells were centrifuged at 400g
for 10 min. Cells were washed three times with 10 ml of
phosphate buffered saline (pH 7.4) and fixed in 2%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) overnight
at 4 8C. Cells were postfixed in 1% osmium tetroxide (OsO4)
for 1 h, cells washed twice with water and dehydrated through
a series of alcohols (30–100%) and the cells were embedded
in Embed 812 resin. Thin sections were cut at 80 A, stained
with uranyl acetate and lead citrate and examined under a
JEOL 100CXII transmission electron microscope. For
enumeration of virus particles on the surface of cells,
C8166 cultures were inoculated with equivalent amounts of
each virus for 5 days and cultures processed as described
above. The number of particles associated with 50 different
cells was determined and the mean number of particles
calculated per infected cell.
Macaques analyzed in this study
Three 1–1.5 year old pig-tailed macaques (Macaca
nemestrina; CX59, CX58, CW1K) were inoculated intra-
venously with 1 ml of undiluted supernatant from C8166-
grown stocks of virus containing 104 TCID50 per milli-
liter. These macaques were euthanized at 24–32 weeks
following inoculation. The inoculated macaques were
compared to macaques inoculated with SHIVKU-1bMC33
(pathogenic virus) and those inoculated with novpuSH-
IVKU1bMC33 as previously described (Hout et al., 2004;
Singh et al., 2003; Stephens et al., 2002). The animals
were housed in the AAALAC-approved animal facility at
the University of Kansas Medical Center. Heparinized
blood was collected weekly for the first 4 weeks, then at
2-week intervals for the next month, and thereafter at
monthly intervals.
Assays for circulating CD4+ T cells
Alterations in the levels of CD4+ lymphocytes after
experimental inoculations were monitored sequentially by
FACS analysis (Becton Dickinson). T lymphocyte subsets
were labeled with OKT4 (CD4; Ortho Diagnostics Systems,
Inc), SP34 (CD3; Pharmingen) or FN18 (CD3; Biosource
International) monoclonal antibodies. T lymphocyte subsets
from a normal uninfected macaque were always performed
at the same time as inoculated macaques as a control for the
FACS analysis.Processing of tissue samples at necropsy
At the time of euthanasia, all animals in this study were
anesthetized by administration of 10 mg/kg ketamine (IM)
followed by an intravenously administration of sodium
phenobarbital at 20–30 mg/kg. A laparotomy was performed
and the animal exsanguinated by aortic cannulation and
perfused with one liter of cold Ringer’s saline. All aspects of
the animal studies were performed according to the institu-
tional guidelines for animal care and use at University of
Kansas Medical Center. Lymphoid tissues (lymph nodes,
spleen, and thymus) and non-lymphoid tissues (brain, heart,
kidneys, liver, lung, pancreas, small intestine) were obtained
and aliquots of tissue snap frozen for DNA and RNA assays.
Portions of lymphoid tissues were immersed in Hank’s
buffered saline (HBSS) to quantitate levels of infectious
virus in tissues.
Sequence analysis of the vpu gene
The vpu gene was amplified from several tissue DNA
samples taken at necropsy to examine if the sequence of vpu
was stable. For amplification of the vpu, we used oligonu-
cleotide primers 5V-CCTAGACTAGAGCCCTGGAAGQ
CATCC-3V (sense ) and 5V-GTACCTCTGTATCATATGCT-
TTAGCAT-3V (antisense), which are complementary to
nucleotides 5845–5870 and 6393–6420 of the HIV-1
(HXB2) genome, respectively (Ratner et al., 1985). One
microgram of genomic DNAwas used in the PCR with Taq
DNA polymerase and the conditions described above. For
the second round of amplification, we used oligo-
nucleotide primers 5V-TTAGGCATCTCCTATGGCAG-
GAAGAAG -3V (sense) and 5VCACAAAATAGAGTGGTG-
GTTGCTTCCT-3V (antisense), which are complementary to
nucleotides 5956–5984 and 6386–6413 of the HIV-1
(HXB2) genome (Ratner et al., 1985), respectively. The
conditions for amplification were identical to those described
above. For sequence analysis, the PCR products from three
separate PCRs were separated by electrophoresis in a 1%
agarose gel, isolated, and molecularly cloned into the
pGEM-T Easy vector according to the manufacturer’s
instructions. Cycle sequencing reactions using the BigDye
Terminator Cycle Sequencing Ready Reaction Kit with
AmpliTaq DNA polymerase, FS (PE Applied Biosystems,
Foster City, CA) and sequence detection was conducted
with an Applied Biosystems 377 Prism XL automated
DNA sequencer and visualized using the ABI Editview
program. Sequences were compared to the intact sequences
from SHIVKU-1bMC33.
PCR amplification of viral sequence from tissues
SHIV gag
DNA extracted from the visceral organs and different
regions of the CNS as previously described (McCormick-
Davis et al., 2000b) were used to amplify viral gag
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of amplification were 5V-GATGGGCGTGAGAAACTCCG-
TCTT-3V (sense ) and 5V-CCTCCTCTGCCGCTAGATGGT-
GCTGTTG-3V (antisense) corresponding to the region 1052–
1075 and 1423–1450 of the SIVmac239 gag gene respec-
tively (Regier and Desrosiers, 1990). The nested SIVmac239
primers used were 5V-GAACATGTTGAAGCATGTAG-
TATGGGCAGC-3V (sense) and 5V-CACCACTAGGTGTC-
TCTGCACTATCTGTTTTGC-3V (antisense) which are
complementary to bases 1142–1165 and 1356–1382 of
SIVmac239, respectively.
Long terminal repeat circles
We examined tissue DNA samples for the presence of
2-LTR circular DNA as it provides a view of a spreading
infection based on a viral DNA form that is structurally
distinct and known to have a short half-life in infected
cells (Sharkey and Stevenson, 2001; Sharkey et al., 2000;
Teo et al., 1997; Zazzi et al., 1997). DNA isolated from
visceral organs and 12 regions of the brain was analyzed
for the presence of 2-LTR circular forms of DNA as
previously described (McCormick-Davis et al., 2000b).
The oligonucleotides used in the first round were 5V-
CCTCCTGTGCCTCATCTGATACATTTAC-3V (U5 re-
gion) and 5V-ATTTCGCTCTGTATTCAGTCGCTCTGC-
3V (U3 region), which correspond to bases 10,335 to
10,361 and 180 to 153 of the SHIV genome, respectively.
The PCR amplification was performed using the following
conditions: denaturation at 92 8C for 1 min, annealing at
55 8C for 1 min, and primer extension at 72 8C for 3 min.
One microliter of the first PCR product was used as a
template for a second amplification using the same con-
ditions. The oligonucleotides primers used for the second
round were 5V-TTGGGTATCTAATTCCTGGTCCTGAG-3V
(U5 region) and 5V-AGGTTCTCTCCAGCACTAGCAGG-
TAGAGC-3V (U3 region; opposite strand; 456), which
corresponds to bases 10,389 to 10,417, and 120 to 95 of
the SHIV genome, respectively. The predicted product of the
2-LTR PCR product is 361 base pairs.
Analysis of virus loads in macaques
PCR-ICA
The virus loads in the CNS and lymphoid tissues were
determined using a quantitative PCR assay modified from a
PCR-infected cell assay previously described (Joag et al.,
1994; Stephens et al., 1998). In this assay, 1 Ag of total
cellular DNA isolated from tissues was subjected to a series
of 10-fold dilutions such that samples contained from 100
ng to 10 fg (less than one copy of chromosomal DNA).
These samples were used in nested PCR reactions that
amplified either the h-actin gene of the cell (a single copy
gene) or the gag gene from SHIVKU1bMC33. Amplification
of either gene using the primers previously described was
shown to detect one of the copy of each gene (Joag et al.,
1994). Thus, amplification of the h-actin gene determinedthe number of genome equivalents in each sample, whereas
amplification with the gag primers determined the number
of viral copies per number of genome equivalents. The
values were expressed as the number of viral copies per 106
genome equivalents.
Plasma virus loads
Plasma viral RNA loads were determined on RNA
extracted from 500 Al of EDTA-treated plasma. Virus was
pelleted and RNA extracted using the Qiagen viral RNA kit
(Qiagen, Valencia, CA). RNA samples were analyzed by
real-time RT-PCR using gag primers and a 5VFAM and
3VTAMRA labeled Taqman probe that was homologous to
the SIV gag gene as previously described (Hofmann-
Lehmann et al., 2000). Standard curves were prepared
using a series of six 10-fold dilutions of viral RNA of a
known concentration. The sensitivity of the assay was 100
RNA equivalents per ml. Samples were analyzed in
triplicate and the number of RNA equivalents were
calculated per ml of plasma.Acknowledgments
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